Syntara Limited Syntara Limited

Syntara Limited

SNT

Rank in Stocks #26950
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to... Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Share Price
$0.00948976
Last synced: 2026-11-16
Market Cap
$16.67M
Change (1 day)
-0.39%
Change (1 year)
-49.30%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Syntara Limited (SNT)
EPS as of June 2026 TTM: $0.00
According to Syntara Limited's latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of 0.00, an increase over its 2023 EPS of $-0.01.
EPS history for Syntara Limited from 2003 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) 0.00 -68.70%
2025 0.00 -68.70%
2023 $-0.01 400.00%
2022 0.00 -58.18%
2021 $-0.01 -77.46%
2020 $-0.02 -33.88%
2019 $-0.04 -347.65%
2018 $0.01 -133.56%
2017 $-0.04 14.73%
2016 $-0.04 -185.24%
2015 $0.05 -128.30%
2014 $-0.16 25.41%
2013 $-0.13 -10.62%
2012 $-0.14 -29.75%
2011 $-0.20 20.25%
2010 $-0.17 23.11%
2009 $-0.14 43.48%
2008 $-0.10 -13.13%
2007 $-0.11 35.13%
2006 $-0.08 36.62%
2005 $-0.06 37.79%
2004 $-0.04 361.70%
2003 $-0.01 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 -163,070.27%
DE
$6.01 -162,472.97%
DE
$1.53 -41,529.73%
JP
$3.66 -99,018.92%
CH
$0.45 -12,262.16%
IL

Questions about Syntara Limited's earnings per share (EPS)

What is Syntara Limited's earnings per share (EPS)?

Syntara Limited's earnings per share (EPS) over the last twelve months is $0.00, as of Jun 2026.

What was Syntara Limited's earnings per share (EPS) in 2025?

In 2025, Syntara Limited's earnings per share (EPS) was 0.00, compared with $-0.01 in 2023.

How has Syntara Limited's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Syntara Limited's earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2020 ($-0.02).

How does Syntara Limited's earnings per share (EPS) compare with similar companies?

Syntara Limited's earnings per share (EPS) ($0.00) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.